vs
Side-by-side financial comparison of GLAUKOS Corp (GKOS) and Orchestra BioMed Holdings, Inc. (OBIO). Click either name above to swap in a different company.
GLAUKOS Corp is the larger business by last-quarter revenue ($143.1M vs $30.9M, roughly 4.6× Orchestra BioMed Holdings, Inc.). Orchestra BioMed Holdings, Inc. runs the higher net margin — 20.2% vs -93.4%, a 113.6% gap on every dollar of revenue. On growth, Orchestra BioMed Holdings, Inc. posted the faster year-over-year revenue change (12120.2% vs 35.7%). GLAUKOS Corp produced more free cash flow last quarter ($3.9M vs $-2.3M). Over the past eight quarters, Orchestra BioMed Holdings, Inc.'s revenue compounded faster (606.2% CAGR vs 29.3%).
Glaukos Corp is a medical technology company focused on ophthalmology, developing and commercializing minimally invasive surgical devices, prescription pharmaceuticals and consumer products for glaucoma, corneal diseases and other eye disorders. It operates primarily across North America, Europe and Asia Pacific, serving hospitals, ophthalmology clinics and patients worldwide.
Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.
GKOS vs OBIO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $143.1M | $30.9M |
| Net Profit | $-133.7M | $6.2M |
| Gross Margin | -1.1% | 99.8% |
| Operating Margin | -97.7% | 21.8% |
| Net Margin | -93.4% | 20.2% |
| Revenue YoY | 35.7% | 12120.2% |
| Net Profit YoY | -298.0% | 138.7% |
| EPS (diluted) | $-2.34 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $143.1M | $30.9M | ||
| Q3 25 | $133.5M | $861.0K | ||
| Q2 25 | $124.1M | $836.0K | ||
| Q1 25 | $106.7M | $868.0K | ||
| Q4 24 | $105.5M | $253.0K | ||
| Q3 24 | $96.7M | $987.0K | ||
| Q2 24 | $95.7M | $778.0K | ||
| Q1 24 | $85.6M | $620.0K |
| Q4 25 | $-133.7M | $6.2M | ||
| Q3 25 | $-16.2M | $-20.8M | ||
| Q2 25 | $-19.7M | $-19.4M | ||
| Q1 25 | $-18.1M | $-18.8M | ||
| Q4 24 | $-33.6M | $-16.2M | ||
| Q3 24 | $-21.4M | $-15.4M | ||
| Q2 24 | $-50.5M | $-16.0M | ||
| Q1 24 | $-40.8M | $-13.5M |
| Q4 25 | -1.1% | 99.8% | ||
| Q3 25 | 78.4% | 94.3% | ||
| Q2 25 | 78.3% | 94.5% | ||
| Q1 25 | 77.2% | 94.9% | ||
| Q4 24 | 72.9% | 77.1% | ||
| Q3 24 | 76.6% | 93.1% | ||
| Q2 24 | 76.4% | 94.3% | ||
| Q1 24 | 76.3% | 94.5% |
| Q4 25 | -97.7% | 21.8% | ||
| Q3 25 | -12.3% | -2359.2% | ||
| Q2 25 | -18.3% | -2311.8% | ||
| Q1 25 | -19.4% | -2179.8% | ||
| Q4 24 | -27.2% | -6591.7% | ||
| Q3 24 | -25.5% | -1655.7% | ||
| Q2 24 | -31.3% | -2167.0% | ||
| Q1 24 | -45.6% | -2326.3% |
| Q4 25 | -93.4% | 20.2% | ||
| Q3 25 | -12.2% | -2419.0% | ||
| Q2 25 | -15.8% | -2316.1% | ||
| Q1 25 | -17.0% | -2160.7% | ||
| Q4 24 | -31.8% | -6385.4% | ||
| Q3 24 | -22.1% | -1562.9% | ||
| Q2 24 | -52.8% | -2054.0% | ||
| Q1 24 | -47.7% | -2171.5% |
| Q4 25 | $-2.34 | $0.28 | ||
| Q3 25 | $-0.28 | $-0.40 | ||
| Q2 25 | $-0.34 | $-0.50 | ||
| Q1 25 | $-0.32 | $-0.49 | ||
| Q4 24 | $-0.56 | $-0.42 | ||
| Q3 24 | $-0.39 | $-0.41 | ||
| Q2 24 | $-1.00 | $-0.45 | ||
| Q1 24 | $-0.82 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.8M | $106.5M |
| Total DebtLower is stronger | — | $15.0M |
| Stockholders' EquityBook value | $656.2M | $53.6M |
| Total Assets | $893.5M | $114.9M |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.8M | $106.5M | ||
| Q3 25 | $98.2M | $95.8M | ||
| Q2 25 | $100.8M | $33.9M | ||
| Q1 25 | $114.3M | $49.9M | ||
| Q4 24 | $169.6M | $66.8M | ||
| Q3 24 | $100.1M | $66.9M | ||
| Q2 24 | $68.1M | $65.2M | ||
| Q1 24 | $42.5M | $75.0M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $15.0M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $656.2M | $53.6M | ||
| Q3 25 | $769.5M | $43.7M | ||
| Q2 25 | $765.1M | $295.0K | ||
| Q1 25 | $764.0M | $16.9M | ||
| Q4 24 | $766.9M | $33.0M | ||
| Q3 24 | $668.5M | $46.2M | ||
| Q2 24 | $665.2M | $44.1M | ||
| Q1 24 | $450.7M | $57.2M |
| Q4 25 | $893.5M | $114.9M | ||
| Q3 25 | $999.4M | $104.8M | ||
| Q2 25 | $987.0M | $42.8M | ||
| Q1 25 | $966.2M | $59.1M | ||
| Q4 24 | $974.8M | $76.2M | ||
| Q3 24 | $926.5M | $75.3M | ||
| Q2 24 | $919.7M | $72.4M | ||
| Q1 24 | $933.3M | $82.6M |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 50.85× | ||
| Q1 25 | — | 0.89× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.8M | $-2.3M |
| Free Cash FlowOCF − Capex | $3.9M | $-2.3M |
| FCF MarginFCF / Revenue | 2.7% | -7.4% |
| Capex IntensityCapex / Revenue | 2.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | -0.36× |
| TTM Free Cash FlowTrailing 4 quarters | $-22.5M | $-49.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.8M | $-2.3M | ||
| Q3 25 | $-10.1M | $-14.6M | ||
| Q2 25 | $7.0M | $-15.5M | ||
| Q1 25 | $-18.5M | $-16.6M | ||
| Q4 24 | $507.0K | $-13.5M | ||
| Q3 24 | $-9.6M | $-13.7M | ||
| Q2 24 | $-18.4M | $-10.2M | ||
| Q1 24 | $-33.9M | $-13.1M |
| Q4 25 | $3.9M | $-2.3M | ||
| Q3 25 | $-11.7M | $-14.9M | ||
| Q2 25 | $5.8M | $-15.6M | ||
| Q1 25 | $-20.5M | $-16.7M | ||
| Q4 24 | $-1.2M | $-13.6M | ||
| Q3 24 | $-11.0M | $-13.8M | ||
| Q2 24 | $-20.5M | $-10.3M | ||
| Q1 24 | $-34.8M | $-13.1M |
| Q4 25 | 2.7% | -7.4% | ||
| Q3 25 | -8.8% | -1725.9% | ||
| Q2 25 | 4.7% | -1861.4% | ||
| Q1 25 | -19.2% | -1927.2% | ||
| Q4 24 | -1.2% | -5392.9% | ||
| Q3 24 | -11.4% | -1394.9% | ||
| Q2 24 | -21.4% | -1325.6% | ||
| Q1 24 | -40.7% | -2116.5% |
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 1.2% | 36.0% | ||
| Q2 25 | 0.9% | 4.1% | ||
| Q1 25 | 1.8% | 12.9% | ||
| Q4 24 | 1.6% | 41.9% | ||
| Q3 24 | 1.5% | 6.9% | ||
| Q2 24 | 2.2% | 13.8% | ||
| Q1 24 | 1.1% | 1.3% |
| Q4 25 | — | -0.36× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
OBIO
Segment breakdown not available.
